<?xml version="1.0" encoding="UTF-8"?>
<p id="p0395">The good activities reported for this drug as well as the search for safe and fast therapy for COVID-19 have prompted investigations on atazanavir. Marketed drugs that could act on the viral components of SARS-CoV-2 were analysed by Beck et al.
 <xref rid="b0925" ref-type="bibr">
  <sup>185</sup>
 </xref> through a model of drug-target interaction called Molecule Transformer-Drug Target Interaction (MT-DTI). The binding affinity of 3.410 FDA-approved-drugs against 3CL
 <sup>pro</sup> proteinase, RdRp, helicase, exonuclease 3′–5′, endoRNAse and SARS-CoV-2 2′-O-ribose methyltransferase. Results suggested atazanavir as the best drug because of its strong binding affinity to proteinase 3CL
 <sup>pro</sup> (K
 <sub>d</sub> 94.94 nM), RdRp (K
 <sub>d</sub> 25,92 nM), helicase (
 <italic>K</italic>
 <sub>d</sub> 25,92 nM), 3′-
 <italic>para</italic>-5 'exonuclease (
 <italic>K</italic>
 <sub>d</sub> 82,36 nM), 2′-o-ribose methyltransferase (
 <italic>K</italic>
 <sub>d</sub> de 390,67 nM), and endoRNAse (
 <italic>K</italic>
 <sub>d</sub> 50,32 nM). Therefore, it is likely that atazanavir can inhibit all subunits in the SARS-CoV-2 replication complex at the same time.
</p>
